Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume – Here’s Why

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) saw an uptick in trading volume on Tuesday . 2,502,857 shares traded hands during trading, an increase of 65% from the previous session’s volume of 1,513,499 shares.The stock last traded at $20.74 and had previously closed at $20.68.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. HC Wainwright restated a “buy” rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 14th. Finally, Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Price Performance

The company has a market cap of $13.34 billion, a P/E ratio of 11.82, a PEG ratio of 6.98 and a beta of 0.96. The business’s 50 day moving average price is $20.92 and its 200-day moving average price is $20.73.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. As a group, research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its position in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the period. Headlands Technologies LLC raised its stake in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after buying an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares during the period. Lindbrook Capital LLC boosted its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares during the last quarter. Finally, Barclays PLC boosted its stake in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after acquiring an additional 2,285 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.